26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
May 2022 in “Голова и шея.” Exosomes show promise for targeted treatment of HER2-positive breast cancer.